CSL Gains BUY Ratings as FDA Approval and Leadership Appointment Signal Growth Potential
CSL Limited (ASX:CSL) has garnered renewed investor confidence, with analysts issuing BUY recommendations and assigning a target price of AUD 312.99, suggesting a 30.18% upside potential. This follows key developments including the FDA approval of ANDEMBRY®, a pioneering hereditary angioedema (HAE) treatment, and the …
Team Kalkine |
23 Jun 2025| Read Time : 10 Mins